Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 4/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 4/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 4/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.81 |
| ▸ | KIT | P10721 | 7/20 | 0.81 |
| ▸ | KDR | P35968 | 3/20 | 0.81 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.78 |
| ▸ | EGFR | P00533 | 2/20 | 0.72 |
| ▸ | ABL1 | P00519 | 7/20 | 0.72 |
| ▸ | BCR | P11274 | 5/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.72 |
| ▸ | PRKCA | P17252 | 1/20 | 0.71 |
| ▸ | ABL2 | P42684 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29644765 | 0.92 | MAPK8 (0.84) | MAPK8MAPK9MAPK10PDGFRAKIT | |
| SCHEMBL14979766 | 0.92 | MAPK8 (0.84) | MAPK8MAPK9MAPK10PDGFRAKIT | |
| SCHEMBL29416038 | 0.91 | MAPK8 (1.00) | MAPK8MAPK9MAPK10PDGFRAKIT | |
| SCHEMBL14979773 | 0.91 | MAPK8 (1.00) | MAPK8MAPK9MAPK10PDGFRAKIT | |
| SCHEMBL11927815 | 0.89 | PDGFRA (1.00) | MAPK8MAPK9MAPK10PDGFRAKIT | |
| SCHEMBL11927769 | 0.89 | MAPK8 (0.81) | MAPK8MAPK9MAPK10PDGFRAKIT | |
| SCHEMBL11927767 | 0.89 | PDGFRA (0.83) | MAPK8MAPK9MAPK10PDGFRAKIT | |
| SCHEMBL29644766 | 0.88 | EGFR (0.89) | MAPK8MAPK9MAPK10PDGFRAKIT | |
| SCHEMBL14979767 | 0.88 | EGFR (0.89) | MAPK8MAPK9MAPK10PDGFRAKIT | |
| SCHEMBL11927821 | 0.88 | PDGFRA (1.00) | MAPK8MAPK9MAPK10PDGFRAKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-12414981-B2 | JNK inhibitors for use in treating and preventing neurodegenerative disorders | NORTHWESTERN UNIVERSITY (US) | 2025-09-16 | — | — | US | claimed |
| US-12005253-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2024-06-11 | — | — | US | claimed |
| EP-4363043-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2024-05-08 | — | — | EP | claimed |
| CN-117580614-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2024-02-20 | — | — | CN | claimed |
| US-20230062911-A1 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING, AND/OR AMELIORATING CHEMOTHERAPY-INDUCED PREMATURE OVARIAN FAILURE (POF) | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-03-02 | — | — | US | claimed |
| WO-2023275649-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2023-01-05 | — | — | WO | claimed |
| US-20230001193-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | BIOPHARMA CREDIT PLC (GB) | 2023-01-05 | — | — | US | claimed |
| US-20220362335-A1 | JNK INHIBITORS FOR USE IN TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | NORTHWESTERN UNIVERSITY | 2022-11-17 | — | — | US | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250339680-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12383738-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2025-08-12 | — | — | US | disclosed |
| WO-2025090966-A1 | MEK INHIBITORS, ALONE OR IN COMBINATION WITH CDK4/5 INHIBITORS, FOR USE IN TREATING CANCER | VEVO THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20120238593-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8242271-B2 | Heterocyclic compounds and uses thereof | AVILA THERAPEUTICS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242271-B2 | Heterocyclic compounds and uses thereof | AVILA THERAPEUTICS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| WO-2008151183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | MAPK8 3227/4885MAPK9 3901/4885MAPK10 4442/4885 |
| US-20230062911-A1 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING, AND/OR AMELIORATING CHEMOTHERAPY-INDUCED PREMATURE OVARIAN FAILURE (POF) | POF1B, MAPKAPK2, MAPKAPK3 | MAPK8 23/4885MAPK9 47/4885MAPK10 10/4885 |
| US-20120238593-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | MAPK8 3227/4885MAPK9 3901/4885MAPK10 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.